| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2148 | 2018 |
| Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas G Kohanbash, DA Carrera, S Shrivastav, BJ Ahn, N Jahan, T Mazor, ... The Journal of clinical investigation 127 (4), 1425-1437, 2017 | 363 | 2017 |
| Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy ZS Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ... Journal of Experimental Medicine 215 (1), 141-157, 2018 | 210 | 2018 |
| Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors ZS Chheda, RK Sharma, VR Jala, AD Luster, B Haribabu The Journal of Immunology 197 (5), 2016 | 149 | 2016 |
| Immunotherapy of primary brain tumors: facts and hopes RA Buerki, ZS Chheda, H Okada Clinical Cancer Research 24 (21), 5198-5205, 2018 | 77 | 2018 |
| Role of 14-bp deletion/insertion polymorphism in exon 8 of the HLA-G gene in recurrent spontaneous abortion patients U Shankarkumar, A Shankarkumar, Z Chedda, K Ghosh Journal of human reproductive sciences 4 (3), 143-146, 2011 | 53 | 2011 |
| The yin and yang of leukotriene B4 mediated inflammation in cancer VR Jala, SR Bodduluri, SR Satpathy, Z Chheda, RK Sharma, B Haribabu Seminars in immunology 33, 58-64, 2017 | 46 | 2017 |
| A spontaneous metastasis model reveals the significance of claudin-9 overexpression in lung cancer metastasis RK Sharma, ZS Chheda, BP Das Purkayastha, JG Gomez-Gutierrez, ... Clinical & experimental metastasis 33, 263-275, 2016 | 45 | 2016 |
| Expression of leukotriene B4 receptor-1 on CD8+ T cells is required for their migration into tumors to elicit effective antitumor immunity RK Sharma, Z Chheda, VR Jala, B Haribabu The Journal of Immunology 191 (6), 3462-3470, 2013 | 36 | 2013 |
| Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy RK Sharma, ZS Chheda, VR Jala, B Haribabu Expert review of vaccines 14 (4), 537-549, 2015 | 24 | 2015 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Absence of CCR2 reduces spontaneous intestinal tumorigenesis in the ApcMin/+ mouse model VR Jala, SR Bodduluri, S Ghosh, Z Chheda, R Singh, ME Smith, ... International Journal of Cancer 148 (10), 2594-2607, 2021 | 7 | 2021 |
| Correspondence on'H3. 3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma'by Immisch et al ZS Chheda, S Mueller, B Hegde, A Yamamichi, LH Butterfield, H Okada Journal for Immunotherapy of Cancer 11 (3), 2023 | 1 | 2023 |
| Engineering tertiary lymphoid structures for glioblastoma: A novel gene combination promotes therapeutic TLS formation in an immune-competent mouse model of GBM KM Downey, B Hegde, Z Chheda, J Zhang, H Okada Cancer Research 81 (13_Supplement), 74-74, 2021 | | 2021 |
| IMMU-28. INDUCTION OF TERTIARY LYMPHOID STRUCTURE-LIKE T-CELL CLUSTERS BY DELIVERY OF A NOVEL GENE COMBINATION INTO AN IMMUNOCOMPETENT MOUSE MODEL OF GLIOBLASTOMA K Downey, B Hegde, Z Chheda, J Zhang, H Okada Neuro-Oncology 22 (Suppl 2), ii110, 2020 | | 2020 |
| IMMU-38. CRISPR BASED GENOME EDITING OF HUMAN T CELLS TO TARGET H3. 3K27M MUTATION IN GLIOMAS B Hegde, T Roth, D Nguyen, Z Chheda, R Apathy, A Marson, H Okada Neuro-Oncology 21 (Suppl 6), vi127, 2019 | | 2019 |
| IMMU-41. H3. 3K27M MUTATION-DERIVED NOVEL NEOANTIGEN–CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY Z Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ... Neuro-Oncology 19 (suppl_6), vi121-vi121, 2017 | | 2017 |
| Identification of a novel and a shared H3. 3K27M mutation derived neoantigen epitope and H3. 3K27M specific TCR engineered T cell therapy for glioma Z Chheda, G Kohanbash, J Sidney, K Okada, N Jahan, D Carrera, ... Cancer Research 77 (13_Supplement), 3767-3767, 2017 | | 2017 |
| CCR2 promotes intestinal tumorigenesis through enhancing inflammation via IL-17 and IL-23 pathway VR Jala, SR Bodduluri, P Chilton, ZS Chheda, RK Sharma, R Singh, ... The Journal of Immunology 198 (1_Supplement), 65.19-65.19, 2017 | | 2017 |
| OS09. 4 Identification of a novel H3. 3. K27M mutation-derived neoantigen epitope and cloning of H3. 3. K27M-specific T-cell receptor for T-cell therapy in gliomas Z Chheda, G Kohanbash, J Sidney, K Okada, N Jahan, S Mueller, A Sette, ... Neuro-Oncology 19 (suppl_3), iii18-iii19, 2017 | | 2017 |
